Emerging Topical and Systemic JAK Inhibitors in Dermatology
Top Cited Papers
Open Access
- 3 December 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 2847
- https://doi.org/10.3389/fimmu.2019.02847
Abstract
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders. Here, the elucidation of key pathogenic factors such as IL-17A/IL-23 on the one hand and IL-4/IL-13 on the other hand profoundly changed our therapeutic practice. The knowledge on intracellular pathways and governing factors is shifting our attention to new druggable molecules. Multiple cytokine receptors signal through Janus kinases (JAKs) and associated signal transducer and activators of transcription (STATs). Inhibition of JAKs can simultaneously block the function of multiple cytokines. Therefore, JAK inhibitors (JAKi) are emerging as a new class of drugs, which in dermatology can either be used systemically as oral drugs or locally in topical formulations. Inhibition of JAKs has been shown to be effective in various skin disorders. The first oral JAKi have been recently approved for the treatment of rheumatoid arthritis and psoriatic arthritis. Currently, multiple inhibitors of the JAK/STAT pathway are being investigated for skin diseases like alopecia areata, atopic dermatitis, dermatomyositis, graft-versus-host-disease, hidradenitis suppurativa, lichen planus, lupus erythematosus, psoriasis, and vitiligo. Here, we aim to discuss the immunological basis and current stage of development of JAKi in dermatology.Keywords
This publication has 238 references indexed in Scilit:
- A randomized phase 2a efficacy and safety trial of the topical J anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasisBritish Journal of Dermatology, 2013
- Diagnosis and Treatment of Lichen SclerosusAmerican Journal of Clinical Dermatology, 2012
- Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesisClinical and Experimental Immunology, 2012
- A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8+ T-Cell Accumulation in the SkinJournal of Investigative Dermatology, 2012
- Functional STAT3 deficiency compromises the generation of human T follicular helper cellsBlood, 2012
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)The Journal of Immunology, 2011
- Genetic susceptibility to systemic lupus erythematosus in the genomic eraNature Reviews Rheumatology, 2010
- Genome-wide association study in alopecia areata implicates both innate and adaptive immunityNature, 2010
- Selectivity and therapeutic inhibition of kinases: to be or not to be?Nature Immunology, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009